AstraZeneca's Pipeline Reaps Rewards Of Return To Science
AstraZeneca rounded off a busy 2017 full of R&D highs, but some huge lows, with a full Phase III pipeline that it says shows how far the company has come since Pascal Soriot took the reins in 2012 and spearheaded a renewed focus on science. But will the company become a victim of its own success?
You may also be interested in...
TULIP Fever: AstraZeneca Catches Cold With Disappointing Lupus Data
Another one of AstraZeneca’s more left-field product candidates, its investigational lupus therapy anifrolumab, has disappointed at Phase III.
Hyperkalemia Market Hots Up In EU with Okay for AZ's Lokelma
Rival Vifor Pharma has predicted blockbuster status for Veltassa and AstraZeneca expects the same for its just-approved oral potassium-removing agent, hoping that Lokelma's faster onset of action will help it win the fight for market share in hyperkalemia.
AstraZeneca Keeps R&D Focus, Spins Out Phase II Neuromyelitis Optica MAb Into New Biotech
Six early-stage biologics with potential to treat inflammation and auto-immunity disorders have been spun out of AstraZeneca's biologics arm, MedImmune, into a stand-alone Chinese investor-backed company, Viela Bio, underlining the commitment of the big pharma to its three areas of therapeutic focus.